Case ReportsCanagliflozin-Associated Acute PancreatitisVerma, Rajanshu MDAuthor Information Department of Hospital Medicine (UHS), United Hospital, Allina Health, St. Paul, MN. Address for correspondence: Allina Health, United Hospitalist Service, 333 N Smith Avenue, St. Paul, MN 55102. E-mail: firstname.lastname@example.org The author has no conflicts of interest to declare. American Journal of Therapeutics: May/June 2016 - Volume 23 - Issue 3 - p e972-e973 doi: 10.1097/MJT.0000000000000135 Buy Metrics Abstract Canagliflozin is a new drug in class of sodium–glucose cotransporter 2 inhibitors used for treatment of type 2 diabetes mellitus. We describe a patient who developed moderately severe acute pancreatitis as an untoward consequence after being initiated on this drug. To the best of our knowledge, this is the first reported case of canagliflozin-associated acute pancreatitis in clinical literature. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.